Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
09 mai 2016 08h38 HE
|
Anthera Pharmaceuticals, Inc.
SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr....
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
27 avr. 2016 16h05 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors. Mr. Furse has over...
Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
10 mars 2016 08h37 HE
|
Anthera Pharmaceuticals, Inc.
SOLUTION clinical study of oral Sollpura™ enrollment to begin soon in EuropeData from BRIGHT-SC study in IgA nephropathy planned for Q2 2016Addition of Craig Thompson as President and Chief...
Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer
07 mars 2016 08h36 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following...
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer
05 janv. 2016 17h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating...
Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
06 nov. 2015 17h18 HE
|
Anthera Pharmaceuticals, Inc.
Closed $29 million public offering in July including full exercise of underwriters’ option to purchase additional sharesCompleted capsule manufacturing in support of the SOLUTION clinical...
Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing of Third Quarter Financial Results
28 oct. 2015 15h03 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company’s attendance at the following healthcare conferences: November 4th,...
Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People With Cystic Fibrosis
02 oct. 2015 12h34 HE
|
Anthera Pharmaceuticals, Inc.
Study to enroll approximately 130 patients with exocrine pancreatic insufficiency
More than 50 clinical sites around the United States and Europe are expected to participate
Anthera to...
Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku
14 sept. 2015 16h30 HE
|
Anthera Pharmaceuticals, Inc.
Anthera will regain all worldwide rights for blisibimod without cost
No patients were enrolled in the BRIGHT-SC study or any other clinical study in Japan
Zenyaku is required to continue...
Anthera Pharmaceuticals Reports 2015 Second Quarter and Operational Update
10 août 2015 16h01 HE
|
Anthera Pharmaceuticals, Inc.
Reached enrollment target of 400 subjects in Phase 3 CHABLIS-SC1 clinical study with blisibimod
Additional data on patient-reported outcomes from Phase 2b PEARL-SC blisibimod clinical study...